← Eichor
Study identifier: NCT04665739 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Condition: Advanced Lung Neuroendocrine Tumor · Functioning Lung Neuroendocrine Tumor · Locally Advanced Lung Neuroendocrine Neoplasm  ·  Sponsor: National Cancer Institute (NCI)

PhasePhase 2
Planned participants70
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Lutetium Lu 177-dotate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Lutetium Lu 177 dotatate may be more effective than everolimus in shrinking or stabilizing advanced bronchial neuroendocrine tumors.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (29)

University of Alabama at Birmingham Cancer CenterBirmingham, Alabama, United StatesWithdrawn
Tower Cancer Research FoundationBeverly Hills, California, United StatesRecruiting
Loma Linda University Medical CenterLoma Linda, California, United StatesSuspended
Cedars-Sinai Medical CenterLos Angeles, California, United StatesRecruiting
UCSF Medical Center-Mission BaySan Francisco, California, United StatesRecruiting
Torrance Memorial Physician Network - Cancer CareTorrance, California, United StatesRecruiting
MedStar Georgetown University HospitalWashington D.C., District of Columbia, United StatesRecruiting
UM Sylvester Comprehensive Cancer Center at AventuraAventura, Florida, United StatesSuspended
UM Sylvester Comprehensive Cancer Center at Coral GablesCoral Gables, Florida, United StatesRecruiting
UM Sylvester Comprehensive Cancer Center at Deerfield BeachDeerfield Beach, Florida, United StatesRecruiting
University of Miami Miller School of Medicine-Sylvester Cancer CenterMiami, Florida, United StatesRecruiting
UM Sylvester Comprehensive Cancer Center at PlantationPlantation, Florida, United StatesRecruiting

+ 17 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04665739